Ubrelvy - (50 and 100 mg ; Tablet)

Generic Name	Ubrogepant	Innovator	Abbvie
Dosage	50 and 100 mg ; Tablet	Branded US Sales	Less Than $1000 mn
Probable FTF	Less Than 5	Known Para IV Filers	Less Than 5
Other ANDA developers	Less Than 5	Tentative Approvals	None
Final Approvals	None	Generic Launches	None
Indication	UBRELVY is a calcitonin gene-related peptide receptor antagonist indicated for the acute treatment of migraine with or without aura in adults.
Complexities	Yes

Executive Summary

Patent Status

Launch Timelines and Competition

Company	FTF Status / 180 days exclusivity	30-Months stay	Current Litigation Status	Current Approval Status	Likelihood of launch
*********	*** \ *********	*** **, ****	*******	****	***** *** ****
***** ******	*** \ *********	*** **, ****	*******	****	***** *** ****
*** ****	*** \ *********	*** **, ****	*******	****	***** *** ****

Chronology Of Events